To synthesize current evidence regarding the neurological safety and efficacy of IBD therapies in the context of demyelinating diseases, particularly multiple sclerosis (MS), and propose specific management strategies for clinicians.
Key Findings:
Individuals with IBD have a 4-fold increased risk of developing demyelinating disorders, particularly MS.
Anti-TNF agents are linked to new-onset or worsening demyelinating events.
Corticosteroids are neurologically safe and can be used as a bridging option in patients with coexisting diseases.
Sphingosine-1-phosphate receptor modulators are effective for both IBD and MS but complicate treatment decisions.
There are no formal guidelines for managing patients with both IBD and demyelinating diseases.
Interpretation:
The coexistence of IBD and demyelinating diseases poses unique challenges in treatment, necessitating careful selection of therapies to avoid exacerbating neurological conditions and emphasizing personalized treatment approaches.
Limitations:
Limited real-world data on the safety and efficacy of IBD therapies in patients with coexisting demyelinating disorders.
Absence of formal guidelines for managing patients with both IBD and demyelinating diseases.
Potential biases in the studies reviewed may affect the conclusions drawn.
Conclusion:
Multidisciplinary collaboration, early recognition of symptoms, and careful treatment selection are essential to optimize outcomes for patients with IBD and demyelinating disorders.
